Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City.
Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and located in New-York. There, he leads the three early pipeline programs, including a novel irreversible BTK inhibitor, and anti-PD-L1 monoclonal antibody and a bispecific antibody directed against CD19 and CD47. All three assets have entered a phase 1 dose-escalation clinical trial in hematologic cancers.
Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention?
A. There has been a recent burst of novel therapies (e.g. cell therapies) that have demonstrated some very spectacular effects, at least in a subset of patients, but also some dramatic severe adverse events. One major challenge for some of these new therapies are their availability, because the toxic effects and the operational complexity do not allow a wide distribution in community hospitals. In part linked to this, these new treatments often suffer from an acute financial toxicity.
Q. What are the new opportunities emerging in your field of work?
A. TG Therapeutics is focused on hematologic cancers, B cell malignancies. In this field, we have seen some major improvement of outcomes (e.g. effects of ibrutinib in CLL), an increase of PFS, and, hence, the need for drugs that can be administered on a time-limited basis. This is a challenge and an opportunity.
Q. What are the key take away points from your presentation topic which will help in building the knowledge base of attendees?
A. The key message of my presentation is that targeted therapies, including biologics and SMEs, can be combined in duo, triad or even quad (e.g. BTKi, PI3Ki, anti-CD20, and anti-CD47) and demonstrate synergistic activities. The presentation focus on recent preclinical work, and allude to existing clinical trial that support this multipronged strategy.
Q. Hope you had a chance to go through the agenda, what are your views on it and how helpful it is to the targeted audience?
Looks good :most of the key topics, like biomarker, checkpoint inhibitor, combination, preclinical models, tumor microenvironment, are addressed.
The number and quality of companies attending is also great for networking.
Emmanuel Normant will present his insights on “Combinations of antibodies and small molecules in the Immuno-Oncology world: A TG Therapeutics perspective”
The latest conference agenda and complete speaker line-up is available to download on the conference page, where you can also register – https://bit.ly/2LNkgpQ
For more inquiries contact Amit Shelke, Marketing Manager on [email protected]
